Roles of pretreatment PLR,NLR and LMR in the prognosis of prostate cancer

doi:10.3969/j.issn.1673-8640.2021.06.012

Abstract

Abstract:

Objective To investigate the roles of pretreatment platelet/lymphocyte ratio（PLR）,neutrophil/lymphocyte ratio（NLR） and lymphocyte/monocyte ratio（LMR） in the prognosis of prostate cancer patients. Methods The clinical data of 144 patients with prostate cancer were enrolled. Pretreatment platelet,lymphocyte,monocyte and neutrophil were determined. PLR,NLR and LMR were calculated. Patients diagnosed with prostate cancer were enrolled for a 3-year follow-up. Kaplan-Meier method was used for survival analysis. Cox regression analysis was used to evaluate the correlations between PLR,NLR and LMR with the prognosis of prostate cancer. The correlations between PLR,NLR and LMR with Gleason scores were analyzed by Pearson analysis. Results PLR,NLR and LMR of 144 prostate cancer patients were 4.71（1.21-62.14）,4.77（1.34-57.41） and 2.83（0.91-39.10）,respectively. The subjects were grouped according to the median of the measured values of the 3 indicators. In patients with high PLR and low LMR,the 3-year overall survival rate,progression-free survival rate and tumor-specific survival rate were decreased（P<0.001）. There was no statistical significance in 3-year overall survival rate,progression-free survival rate and tumor-specific survival rate of prostate cancer patients between high and low NLR groups（P>0.05）. Cox regression analysis showed that high PLR,low LMR,age,alcohol history,hypertension history and TNM stage were prognostic factors for 3-year overall survival rate,progression-free survival rate and tumor-specific survival rate in prostate cancer patients（P<0.05）. Pearson analysis showed that there were positive correlations between PLR and NLR with Gleason score（r=0.26 and 0.23,P<0.01） and a negative correlation between LMR and Gleason score（r=-0.41,P<0.000 1）. Conclusions PLR and LMR before treatment can be used as prognostic indicators for patients with prostate cancer,and patients with pretreatment high PLR and low LMR have poor prognosis.

Key words: Platelet/lymphocyte ratio, Lymphocyte/monocyte ratio, Nutrophil/lymphocyte ratio, Prostate cancer, Prognosis

CLC Number:

R446.1

LI Junsheng, SONG Yunxiao, CHENG Jie. Roles of pretreatment PLR,NLR and LMR in the prognosis of prostate cancer[J]. Laboratory Medicine, 2021, 36(6): 631-636.

Figures/Tables 4

References 12

[1]	刘大可, 王洁, 冯国杉, 等. 上海市长宁区1973—2013年前列腺癌发病率和死亡率趋势分析[J]. 复旦学报(医学版), 2020,47(6):809-815.
[2]	ZAORSKY N G, CHURILLA T M, EGLESTON B L, et al. Causes of death among cancer patients[J]. Ann Oncol, 2017,28(2):400-407. DOI URL
[3]	孙颖浩. 前列腺癌诊治进展[J]. 上海医学, 2011,34(7):487-488.
[4]	赵雅文, 董頔, 薛茜文, 等. 术前外周血中NLR、PLR、LMR与早期宫颈癌患者预后的相关性研究[J]. 新疆医科大学学报, 2020,43(8):997-1003.
[5]	彭维忠, 杨浩洁, 张克兰, 等. 术前外周血NLR和PLR在结直肠癌预后评估中的价值[J]. 中国免疫学杂志, 2019,35(4):471-475.
[6]	魏高辉, 孟宪春, 宋倩倩, 等. 血小板淋巴细胞比和中性粒细胞淋巴细胞比辅助筛查前列腺癌患者的作用研究[J]. 中国男科学杂志, 2015,29(10):25-30.
[7]	胡小剑, 郑亮, 张志刚, 等. 前列腺癌根治术患者治疗前后血小板/淋巴细胞比值变化及其与预后相关性分析[J]. 实用癌症杂志, 2020,35(9):1558-1561.
[8]	MA Y, ZHANG J, CHEN X. Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy[J]. Cancer Manag Res, 2021,13:1571-1580. DOI URL
[9]	ANWAR S L, CAHYONO R, AVANTI W S, et al. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression:a retrospective cohort study[J]. Ann Med Surg(Lond), 2021,63:102144.
[10]	LIU K, JIANG G, FANG N, et al. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer[J]. J Int Med Res, 2020,48(12):300060520980205.
[11]	闫传武, 赵江. 术前外周血血小板/淋巴细胞比值与前列腺癌患者临床病理特征及根治术后生存时间的相关性分析[J]. 国际泌尿系统杂志, 2019,39(1):5-9.
[12]	王宁, 刘建业, 邓敏华, 等. 中性粒细胞与淋巴细胞比值对接受全雄激素阻断治疗的前列腺癌患者预后的影响[J]. 中华泌尿外科杂志, 2018,39(12):911-915.

[1]	SUN Chuanyu, ZHAO Xiaojun, GE Shengyang, ZHANG Yang. Transcription factors in prostate cancer progression [J]. Laboratory Medicine, 2023, 38(9): 818-824.
[2]	WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841.
[3]	PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854.
[4]	ZHANG Han, LI Jun, LIU Xiaojiang, GUAN Yixiang. Role of serum albumin，interleukin-6 and ferritin combined determination in evaluating the functional prognosis of patients with spontaneous intracerebral hemorrhage [J]. Laboratory Medicine, 2023, 38(8): 713-718.
[5]	ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765.
[6]	GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679.
[7]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[8]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.
[9]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[10]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[11]	LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214.
[12]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[13]	WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195.
[14]	GU Yi, WANG Rui, DENG Jie, YANG Yijing, ZHOU Wangke, CHEN Yunuo, CHEN Xiaosong, SHEN Wei, ZHOU Jingyi. Differential analysis and prognostic diagnostic value of inflammatory biomarkers in liver transplantation in patients with severe hepatitis and cirrhosis [J]. Laboratory Medicine, 2023, 38(11): 1044-1051.
[15]	LIANG Weizhang, SHI Jianping, CHAI Lina, HAN Aizi. Relationship between serum cathepsin K and ADAMTS-7 with ventricular remodeling and prognosis in patients with chronic heart failure [J]. Laboratory Medicine, 2023, 38(10): 919-925.